(Q41899882)

English

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

scientific article published on 22 November 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Andreas Hochhaus

8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Richard A. Larson

5

object named as

Richard A Larson

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

10

0 references

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jorge Eduardo Cortes

18

object named as

Jorge Cortes

1 reference

Europe PubMed Central

13 October 2017

PMC publication ID

Giovanni Martinelli

12

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

13 October 2017

PMC publication ID

Michele Baccarani

17

object named as

Michele Baccarani

1 reference

Europe PubMed Central

13 October 2017

PMC publication ID

Norbert Gattermann

6

object named as

Norbert Gattermann

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jerald P Radich

9

object named as

Jerald P Radich

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Philipp le Coutre

19

object named as

Philipp D le Coutre

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

14

object named as

Yaping Shou

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Francis J Giles

2

object named as

Francis J Giles

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Javier Pinilla-Ibarz

4

object named as

Javier Pinilla-Ibarz

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Rick E Blakesley

16

object named as

Rick Blakesley

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

3

object named as

Kapil N Bhalla

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

author name string

Timothy P Hughes

11

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Dong-Wook Kim

13

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Neil J Gallagher

15

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

language of work or name

0 references

publication date

22 November 2010

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

117

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1141-1145

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

The biology of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

5 June 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4916554

18 August 2018

Identifiers

10.1182/BLOOD-2010-03-277152

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41899882&oldid=2212037874"